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Abstract
Background—The study hypothesis is that administration of inhaled NO plus oxygen to subjects 
with submassive pulmonary embolism (PE) will improve RV systolic function; reduce RV strain 
and necrosis while improving patient dyspnea more than treatment with oxygen alone.
Methods—This paper describes the rationale and protocol for a registered (NCT01939301), a 
nearly completed Phase II, three-center, randomized, double blind, controlled trial. Eligible 
patients have pulmonary imaging-proven acute PE. Subjects must be normotensive, have RV 
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dysfunction on echocardiography or elevated troponin or brain natriuretic peptide and no 
fibrinolytics. Subjects receive NO plus oxygen or placebo for 24 hours (±3 h) with blood sampling 
before and after treatment, and mandatory echocardiography and high sensitivity troponin post 
treatment to assess the composite primary endpoint. The sample size of N=78 was predicated on 
30% more NO-treated patients having a normal high sensitivity troponin (<14 pg/mL) and a 
normal RV on echocardiography at 24 hours with α=0.05 and β=0.20. Safety was ensured by 
continuous spectrophotometric monitoring of %methemoglobinemia, and a predefined protocol to 
respond to emergent changes in condition. Blinding was ensured by identical tanks, software and 
physical shielding of the device display and query of the clinical care team to assess blinding 
efficacy.
Results—We have enrolled 78 patients over a 31 month period. No patient has been withdrawn 
stopped as a result of a safety concern, and no patient has had a serious adverse event related to 
NO.
Conclusions—We present methods and a protocol for the first double-blinded, randomized trial 
of inhaled NO to treat PE.
Keywords
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Background and Scientific Rationale
Current standard treatment for acute pulmonary embolism (PE) focuses on reducing clot 
burden with anticoagulant and fibrinolytic agents1. However, experimental models of PE 
have shown that the majority of the increased pulmonary vascular resistance (PVR) during 
PE comes not from the obstructing clot, but rather from vasoconstriction2. Acute PE can 
abruptly increase the systolic pressure in the right ventricle (RV), producing turbulent flow 
across the tricuspid and pulmonic valves immediately proximal to the pulmonary 
vasculature, a compartment that depends on steady state production of nitric oxide (NO) to 
maintain its low resistance (Figure 1). The turbulent flow across the tricuspid and pulmonic 
valves results in hemolysis with subsequent release of free hemoglobin and heme (both of 
which scavenge NO), as well as release of arginase-1 (which reduces plasma L-arginine, the 
substrate of endothelial NO synthase). 3-6 Taken together, these influences may reduce NO 
availability to pulmonary vascular smooth muscle cells, thus further increasing the PVR and 
leading to a vicious cycle of increased PVR, increased RV pressures and more hemolysis. In 
addition to these pulmonary vascular effects, acutely elevated RV pressure causes shear 
injury to the RV muscle, resulting in severe inflammatory injury within 18 hours.7,8 This 
cycle can cause RV failure, shock and death, occurring most commonly within 24 hours of 
acute PE.9 Lastly, even if the acute PE does not lead to mortality, serious long-term 
complications may arise. In fact, survivors of PE that produces acute RV dysfunction may go 
on to experience chronic shortness of breath and exercise intolerance.10 These observations 
provide a rationale for limiting increases in PVR in acute PE. Given the NO deficiency state 
occurring in acute PE, administration of NO makes biological sense. Indeed, a phase I pilot 
study of inhaled NO in eight patients with PE found no evidence of clinical worsening with 
inhaled NO.11 These observations prompted the inhaled NO for PE (iNOPE) trial.
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Trial conduct and registrations
The study protocol and execution was guided by a multidisciplinary group, representing 
disciplines of emergency care (JAK, AEJ, MAP), critical care and pulmonology (TL), 
cardiology (RM) and clinical trials specialist (CLH). The study was overseen in part by 
representatives from the NIH, and Mallinckrodt Pharmaceuticals (formerly IKARIA, Inc.). 
The safety and efficacy of the trial was overseen by a four-person independent data safety 
monitoring board in accordance with an NIH-approved independent charter (see appendix). 
The data coordinating center was overseen by an independent statistician (Anthony Perkins, 
MS). The trial was being conducted under an investigational new drug exemption from FDA 
in accordance with a letter from the Food and Drug Administration (FDA), responding to 
our January 24, 2013 1571 submission. This trial was registered on Clinicaltrials.gov on 
August 28, 2013 (NCT01939301). Trial oversight was in accordance with the Code of 
Federal Regulations (21CFR312), Good Clinical Practice Guidelines and International 
Conference on Harmonization Guidelines. The iNOPE protocol and informed consent forms 
were approved by the Institutional Review Boards of Indiana University School of Medicine 
and the University of Mississippi Medical Center in 2013.
Study design
iNOPE is a multicenter randomized, double-blind, controlled trial of inhaled NO + oxygen 
versus nitrogen + oxygen in subjects with acute submassive PE and RV dysfunction. Study 
drug or placebo was administered with a commercially available, FDA-cleared device 
(INOvent, ® Mallinckrodt Pharmaceuticals, Clinton, NJ). A prior randomized trial of 
inhaled NO for acute chest syndrome in sickle cell anemia patients had demonstrated the 
feasibility of blinding.12
Trial funding
The trial was sponsored by the National Institutes of Health (UM1HL113203-01 to JAK) 
and by an investigator initiated grant from Ikaria Pharmaceuticals, who manufactured the 
INOvent® device in 2013; Ikaria was acquired by Mallinckrodt Pharmaceuticals in 2015. 
Additional funding and the COBAS device for high sensitivity troponin T measurements 
was obtained through an investigator initiated contract with Roche. The sponsors had no role 
in the protocol design have had and will have no role in data analysis presentation or 
manuscript writing.
Inclusion and exclusion criteria
Patients were enrolled under the scientific premise that the presence of RV dysfunction 
worsens outcome from PE.13,14 Given that the hypothesized biological basis of action for 
NO is pulmonary vasodilation with reduction in RV pressure, the inclusion criteria required 
evidence of RV dysfunction. RV dysfunction was indicated by either abnormal biomarker 
values (including an elevated BNP > 90 pg/mL or an FDA cleared, laboratory troponin I 
concentration elevated above the 99th percentile at a coefficient of variability <10%, 
generally >0.1 ng/mL), evidence of RV dilation and/or hypokinesis on echocardiography, or 
an RV:LV ratio >1.0 as observed on CT scan. 13-15 To avoid confounding effects of 
fibrinolysis, which appears to resolve RV dysfunction more rapidly than anticoagulation 
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alone, we excluded patients who had recently received fibrinolysis by any route. To avoid 
possible drug synergy that might cause hypotension, we excluded patients taking organic 
nitrates, phosphodiesterase 5 inhibitors, or soluble guanylate cyclase stimulators. The 
explicit inclusion and exclusions are in Box 1.
Patients were enrolled at three hospitals (Methodist Hospital and The Sidney and Louis 
Eskenazi Hospital in Indianapolis, IN, and the University of Mississippi Medical Center 
Hospital in Jackson, MS). Daily screening consisted of a research specialist review of the 
formal dictation report of either contrast enhanced computerized tomographic angiography 
of the chest or ventilation-perfusion scintillation lung scans, identified by standing query of 
electronic orders. The research specialists, with input and assistance as needed from a site 
PI, then further reviewed each apparently positive study for evidence of RV strain as 
required in the inclusion criteria and for other eligibility criteria, followed by physical 
approach for possible informed consent. Patients were approached in the emergency 
department, intensive and intermediate care units, and rarely in ward setting.
Primary efficacy endpoint
As a phase II study, the endpoint was primarily physiological, in the form of RV function. 
All patients had a formal transthoracic echocardiogram and high sensitivity troponin 
measurement that was paid for by the study, both performed after 24 hours of treatment with 
NO or placebo. The study authors reasoned that an effective treatment should be more likely 
to completely normalize RV function after 24 hours of treatment compared with placebo. All 
patients were treated with an accepted regimen of systemic anticoagulation such as low 
molecular weight heparin, unfractionated heparin, or a direct acting anti-Xa antagonist. The 
formal definition of normal RV function and viability requires normal RV size (<42 mm in 
diastole) and TAPSE >16 mm and normal right ventricular index of myocardial performance 
(RIMP) (<0.40 using spectral Doppler or < 0.55 using tissue Doppler) and normal fractional 
area of contraction (FAC) (>33%) and a serum high sensitivity troponin T hsTnT <14 pg/mL 
(Roche COBAS, Indianapolis, IN) as a marker of RV myocyte necrosis.16,17 Missing values 
will be considered normal.
Study Hypothesis
We hypothesize that the administration of inhaled NO + oxygen to subjects with submassive 
PE will improve RV systolic function, reduce RV strain and necrosis (as assessed by hsTnT), 
and improve dyspnea more than nitrogen + oxygen treatment. Clinical efficacy will be 
defined as the percentage of subjects in each group who have a normal RV size, TAPSE and 
RIMP and FAC on the echocardiogram and a hsTnT concentration <14 pg/ml after 24 hours 
of treatment with inhaled NO + oxygen (intervention) or nitrogen + oxygen (placebo).
The clinical trial also has three secondary endpoints and secondary clinical hypotheses to be 
tested:
1. NO + oxygen will reduce RV strain as assessed by composite of serum BNP<90 
pg/mL RV hypokinesis and a Borg score ≤2 (very slight dyspnea) assessed at the 
end of 24 hours of treatment.
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2. Test if NO + oxygen reduces blood viscosity and attenuates platelet-associated 
clotting kinetics observed on thromboelastography (TEG).
3. Test if NO + oxygen improves perceived dyspnea and perception of wellness 
with a standardized survey at 3 months (SF36 and PEmb QoL).18
The primary safety endpoint was the clinical care team's decision to unblind because of 
perception of clinical deterioration during treatment. Secondary safety endpoints include 
need for rescue therapy, including need for mechanical or noninvasive ventilatory support, 
systemic or catheter based fibrinolysis, or catheter or surgical embolectomy. In-hospital 
serious adverse events were followed for 5 days after treatment ends. At 28 days, patients 
were assessed by for potential study drug related adverse events. Stopping criteria were 
planned according to the method of Lan and DeMets if patients had met an adverse event or 
clinical deterioration criteria, defined as: respiratory distress prompting the clinical care 
team to plan for mechanical or noninvasive ventilatory support, hypoxemia (SpO2 < 90% for 
15 min), or circulatory shock (SBP< 90 mm Hg for 15 min in consecutive measurements), 
new neurologic signs or any ventricular arrhythmias or sustained supraventricular 
arrhythmia with hypotension or refractory to intravenous medication for more than one hour, 
and methemoglobin (MtHb) levels >10% for more than one hour. Pulse oximetry (SpO2%), 
transcutaneous mtHb and carboxyhemoglobin were measured with the Masimo Rainbow® 
Cooximeter device (Masimo Corporation, Irving, CA).
Ancillary basic science study
Under the UM funding mechanism from NHLBI, the study has several preplanned basic 
science studies being performed on blood samples from patients. These measurements are 
summarized as follows:
1. Platelet mitochondrial oxygen consumption (Oxygraph-2k Oroboros 
Instruments, Innsbruck, Austria) and clotting propensity, assessed with whole 
blood thromboelastography with ADP and arachidonic acid agonists 
(Haemoscope 5000, Haemonetics, Braintree, MA) together with measurements 
of cellular apoptosis. The hypothesis is platelets will be hyperactivated and 
apoptotic in PE patients compared with healthy controls, and that platelet 
hyperactivation will be attenuated with NO treatment.
2. Measurements of hemolysis markers LDH, free hemoglobin, haptoglobin, 
hemopexin and carboxyhemoglobin. The hypothesis is that there will be a more 
complete reduction in these biomarkers with NO treatment.
3. Plasma nitrite, nitrate and asymmetric dimethyl arginine (ADMA, an inhibitor of 
endothelial nitric oxide synthase, eNOS) concentrations. The hypothesis is PE 
patients have decreased nitrite+nitrate and elevated ADMA concentrations at 
baseline compared with healthy controls.5
4. Sequencing of the eNOS gene to test for common sequence variations affecting 
treatment responses. Buffy coat will be recovered and stored at -80°C for 
genotypes that predict response to NO therapy. Two common polymorphisms(- 
786T>C and 894G>T) will be assessed with a 5′-allele discrimination PCR 
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assay using primer sequences previously described by our group and others.19,20 
Both polymorphisms impair eNOS synthesis of endogenous NO, impair 
endothelial-induced vascular smooth muscle relaxation, increase red cell fragility 
and increase the risk of PE in Caucasians and Asians.20-22 The hypothesis is that 
patients with these variations will have improved response to inhaled NO.
5. Measurement of cell free circulating plasma nucleic acids (total plasma cell free 
DNA and RNA content), which we hypothesized to increase with PE, possibly as 
a result of neutrophil apoptosis and RV necrosis.23 We hypothesize that RV 
myolysis will also liberate CF DNA/RNA which contributes to thrombin 
generation and increased blood viscosity in the right heart.24 Of fundamental 
importance to this hypothesis, the RV venous drainage returns to right atrium via 
the coronary sinus where it can potentially synergize with platelet-derived 
thrombin generation to increase blood viscosity and RV workload. In addition to 
measuring total CF DNA/RNA, with quantitative rtPCR, we will provide 
evidence of association with RV damage by quantifying three RNAs: 1. Troponin 
T (gene ID X74819), a gene specifically overexpressed in the heart.25 2. 
Natriuretic peptide precursor B (gene ID 4879), a gene that we have previously 
shown by microarray analysis to be specifically upregulated in the RV outflow 
tract with PE26 and 3. microRNA 134, found to be a good diagnostic biomarker 
for PE that is specifically increased in the plasma of humans27. The hypothesis is 
that there will be a more complete and rapid reduction with NO treatment.
Summary of study protocol
The study measurements are shown in Table 1, and the overall flow of the study is 
diagrammed in Figure 2. At baseline, a blood sample was obtained before initiation of study 
drug to allow for a high sensitivity troponin I measurement and for ancillary studies. Blood 
was drawn, stored, and processed according to study standard operating procedures. Because 
of funding limitations, echocardiography has to be performed as part of usual care and 
therefore cannot be performed as a study procedure before the study drug wass delivered. 
Study drug was delivered by a commercial device (INOvent®) via nasal cannula induced at 
2 ppm/min, increased to 50 ppm and maintained for 24h (+/- 3 hrs.) with oxygen delivered at 
3-5 LPM as the carrying gas for study drug delivery.
A study-funded transthoracic Doppler-echocardiogram was obtained within 3 hours of 
weaning of the study drug. Echocardiography was performed by registered diagnostic 
cardiac ultrasonographers operating from an ICAEL-certified echocardiography laboratory. 
Echocardiography images were interpreted for the primary outcomes (RV size, RIMP, 
TAPSE and FAC) using explicit criteria and recorded on a standard form by a central 
cardiologist-echocardiography expert (RM). A second blood sample was obtained after 24 
(+/-3h) of NO, before study drug wean for the high sensitivity tropoinin and BNP 
measurements required for the aims. Subjects were followed for serious adverse events 
through their inpatient stay (through hospital day 5 or discharge, whichever was first) and 
until 28 days for study drug-related adverse events. Subjects will also be contacted at 3 
months for completion of a questionnaire on dyspnea symptoms and quality of life (SF36 
and PEmb QOL surveys).
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Titration dosing and weaning protocol
Titration and weaning procedures were performed by trained research personnel with on-site 
assistance from the manufacturers of the INOvent® device. NO was titrated at 2 ppm/min 
over 25 min to a dose of 50 ppm via nasal cannula as described in Figure 3. Persons 
administering iNO included RRTs or study-specific research coordinators trained by 
personnel from Ikaria. In the phase I study, the PI used 25 ppm NO delivered by a specially 
designed face mask for four hours. However, several patients had considerable discomfort 
and requested to remove the mask.11 Anticipating patient noncompliance with a mask, 
especially overnight, the authors therefore elected to use a nasal cannula for NO delivery. 
The 50 ppm dose was chosen since the nadir in PVR found in dose-response studies of 
secondary pulmonary hypertension was observed at that dose, and since up to 80 ppm was 
well tolerated in a recent clinical trial of NO for acute chest syndrome in subjects with sickle 
cell disease.12,28 Subjects in that trial were treated for up to 72 hours. We chose 24 hours in 
our protocol because the majority of deaths directly attributed to PE occur within 24 hours, 
and because placebo groups in RCTs of fibrinolytic agents that measured PA pressures at 
2-72 hours post treatment found 24 hours sufficient for PVR to decrease.29-33 From the 
outset, we justified the three hour variance based on expectations of imprecise time of arrival 
of echocardiography, and to prevent the weaning procedure from interrupting of standard 
care procedures. Blood samples were drawn immediately prior to weaning to measure 
plasma nitrite and nitrate concentrations to assess NO delivery. After patients received 24 
hours (+/- 3h) of inhaled NO at 50 ppm and were then weaned at 2ppm per minute to 0 ppm 
NO over 25 min.
Patient safety concerns
Treatment with 50 ppm NO for 24 hours (+/- 3 h) may cause mtHb values to exceed 5%. 
This was expected to occur in 1-2 subjects; mtHb levels were therefore continuously 
monitored. NO could theoretically cause hypotension, and for this reason, we exclude use of 
drugs known to increase cGMP. Blood pressure values were monitored closely. NO 
treatment could also theoretically increase risk of lung injury by producing peroxynitrite in 
the alveoli. We continue to monitor for evidence of acute lung injury for 5 days and report 
any to the DSMB. We anticipated that 5 to 10 participants would experience a dry nose from 
the oxygen delivered by nasal cannula for 24 hours (+/- 3 h).
The primary safeguard to prevent immediate harm during treatment was the algorithm 
presented in Figure 3. The algorithm has multiple feedback loops that raise or lower the iNO 
concentration in response to the subject's status. To improve safety, one member of the study 
team (PI or their designee) was not be blinded to treatment, and was available throughout the 
treatment. The DSMB meets regularly to review unblinded data and uses explicit stopping 
criteria for evidence of harm or futility (see DSMB charter in supplement). The SpO2%, 
mtHb% and COHb% was continuously monitored during NO delivery, and Borg score and 
blood pressure was monitored hourly for the first four hours and then per hospital policy. 
The protocol allows for one tank per patient, and each tank has up to 100 hours of drug 
delivery, at no charge to the patient. In the event of severe symptoms, the recommended 
procedure was to unblind the patient, and if the patientreceiving NO, to decrease the inspired 
NO to 25 ppm and observe for either clinical worsening or improvement, and allow that 
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response to guide decisions about continuing or discontinuing NO. If the patient were 
receiving nitrogen + oxygen, then standard care would have proceeded. For the care of 
suspected worsening related directly to PE, we provided a suggested “rescue algorithm” that 
follows ACCP guidelines. It is possible for NO + oxygen to combine to form the irritating 
gas, NO2. The machine that delivers the treatment will continuously monitor for this and 
will sound an alarm if >2 ppm of NO2 were formed.
Sample size, power and statistical analysis—Sample size was predicated on the 
effect size defined as a 30% difference in the independent proportions of patients in each 
group who reach the primary efficacy endpoint (denoted p1 and p2 below), which was 
justified as the minimum effect size to warrant a phase III trial. Prior work that has 
performed repeated echocardiograms in patients receiving heparin only allow the assertion 
of a >90% probability that fewer than 15% of patients will normalize their RV size and 
function within 24 hours of standard treatment.34-36 The nature of the binomial distribution 
used in the test for independent proportions results in a power to detect a difference that 
varies on sample and effect size but also the values of p1 and p2 as diagrammed in Figure 
4.37 Accordingly, in a conservative case estimate of p1=0.15 and p2,=0.45, n=35 per group 
or N=70 total was required to yield a power of 0.80. To account for possible withdrawals or 
unexpectedly high p1, we have estimated need for n=39 per group or N=78.
Sample size/power calculation:
α = 0.05 (probability of type I error); Zα/2 = 1.96; β = 0.20 (probability of type II error); Zβ 
= 0.842
p1 = proportion of patients treated with placebo who normalize RV size and function at 24 
hours
p2= proportion of patients treated with NO who normalize RV size and function at 24 hours; 
p = (p1+p2)/2; δeffect = p1-p2
N = [Zα/2(2p(1-p))1/2 + Zβ(p1(1-p1) +p2(1-p2)) ½]2/δeffect2 =78
Intent to treat was defined as follows: presence of the necessary data to assess the 24 hour 
primary efficacy endpoint (death, or survival with either echocardiography positive, hsTnT 
positive, or both echocardiography an hsTnT normal as described above); otherwise the 
patient will be censored from analysis. Patients who discontinue their original assigned 
group will be analyzed in the original group, and the denominator used to calculate the 
proportion of patients reaching the primary efficacy endpoint in that group.
Randomization and Blinding
The randomization and blinding procedure was also described by a specific guidance 
document and is also explained with photographs in the supplement. This was a randomized, 
double-blinded trial. The identity of the study drug being delivered to the subjects (i.e., 
either NO + oxygen or nitrogen + oxygen) was concealed according to the randomization 
and blinding guidance document. Briefly, this required one non-research team person 
(referred to as the blinder) to receive and conceal study drug canisters from the industry 
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source (Mallinckrodt Pharmaceuticals) and label them externally with the patient ID that 
covered the label from the industry source which indicated the container contents. One 
canister was used per patient and except for differing identification numbers, (e.g., 
“ESKZ-10”), all canisters appear identical. The patient ID was linked to treatment allocation 
in a list maintained by the study statistician, the safety monitor, and the blinder, who all can 
be aware of the assignment. Subjects, caretakers, and the research team have and will not be 
aware of the identity of the canisters unless they open the unblinding envelope. During 
titration, treatment and weaning, the INOvent® delivery system conceals the identity of the 
inspired study drug using Mallinckrodt Pharmaceutical's proprietary blinding software, and 
an opaque metal hood with a narrow vertical window was flipped down during drug 
delivery. While the patient was on protocol, an observer looking through this window could 
only see that the patient was receiving “50 ppm NO”, regardless of treatment assignment by 
the randomization sequence. The blinding shield was intended to prevent any curious person 
from scrolling through menus and possibly seeing the NO2 feedback monitoring system, 
which would potentially unblind the treatment (although this would require a password that 
even study personnel did not know). Sealed envelopes contain subject ID-specific enrollment 
cards and indicate what the subject did receive. Enrollment packets contain a checklist, data 
collection templates, informed consent document, and tubes for blood draws. Each 
unblinding envelope was a pre-sealed, opaque envelope labeled with the subject ID and the 
notation “Open only to unblind” with a letter explaining the treatment assignment. The letter 
asks the name of the unblinder and reason for unblinding. This envelope was readily 
available to all staff.
Discontinuation of study drug: Absolute endpoints include respiratory distress prompting the 
clinical care team to plan for mechanical or noninvasive ventilatory support, hypoxemia 
(SaO2 < 90% for 15 min) requiring intervention, circulatory shock (SBP< 90 mm Hg for 15 
min in consecutive measurements) requiring fluids or vasopressors, any ventricular 
arrhythmias or sustained supraventricular arrhythmia with hypotension or refractory to 
intravenous medication for more than one hour, ECG changes, MtHb >10% for more than 
one hour, or persistent vomiting. Relative endpoints in Figure 3 include persistent symptoms 
or signs, that in the judgment of the investigator, were worsened by reduction in inhaled NO 
ppm and improved by increasing the inhaled NO ppm.
Results
The first patient was enrolled in March 2014, and to date, the study has enrolled 82 patients 
with 8 screen failures and two voluntary withdrawals leaving 78 patients treated per protocol 
with the last patient enrolled in late October, 2016. To reach this number, approximately 
1500 patients with PE have been screened, and 155 were approached for informed consent, 
yielding a consent rate of approximately 50% per patient approached. No patient has been 
discontinued from iNO for a safety reason. No patient experienced hypotension or any other 
adverse event during NO titration. Two patients have been unblinded, in one case in a patient 
who died during an attempted clot extractionprocedure 48 hours after treatment. This patient 
had metastatic adenocarcinoma of the colon and underwent attempted extraction of a large 
right atrial thrombus using the Angiovac device and suffered cardiac arrest during the 
procedure. and in a second patient who had worsened symptoms during treatment. Four 
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patients treated per protocol (4/78) have died within 28 days. No serious adverse event has 
been found to be probably or definitely related to study drug. The DSMB has met as 
scheduled, including the final meeting that allowed the study to proceed to its final sample 
size. We anticipate study completion by the end of calendar year 2016.
Discussion
This paper presents the rationale and protocol for the first phase II study of NO + oxygen to 
treat acute PE. To our knowledge, this is the first detailed description of the methodology to 
conduct a randomized, placebo controlled, double-blind trial using inhaled nitric oxide at 50 
ppm via nasal cannula. To maintain blinding, we use tanks supplied by the manufacturers of 
the commercial device (INOvent®) that are identical for placebo and NO. Because INOvent 
machines have a display that measures both NO and NO2, this portion of the display was 
concealed with a flip-down hood during drug delivery. To ensure integrity of blinding, we 
surveyed the clinical care team. For safety, we created a predefined titration and weaning 
algorithm, shown in Figure 3, and a procedure for handling emergent change in condition, 
consisting of unblinding of an envelope attached to the INOvent® machine, and a rapid 
wean protocol. Although two patients voluntarily withdrew because of the perception that 
they could be discharged sooner, no patient was stopped on protocol because of a safety 
concern. Use of the Masimo Rainbow device has allowed continuous transcutaneous 
spectrophotometric monitoring of the blood percentage of methemoglobinemia. No patient 
has had methemoglobin percentage value that exceeded 10% for longer than 10 minutes. No 
patient has had an adverse event thought to be related to NO. With 78/78 patients enrolled, it 
appears this research protocol is both feasible and safe for patients. This work serves as a 
reference for future investigators to use NO in similarly ill patients (e.g., acute exacerbation 
of pulmonary hypertension from other causes) or the use of other inhaled agents (e.g. 
epoprostenol) for patients with acute PE.
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ED emergency department
eNOS endothelial nitric oxide synthase
FDA Food and Drug Administration
GC guanylate cyclase
ICAEL International committee for accreditation of echocardiography laboratories
IRB institutional review board
mtHb met hemoglobin
NO nitric oxide
OAT ornithine aminotransferase
ODC ornithine decarboxylase
PCR polymerase chain reaction
PE pulmonary embolism
PVR pulmonary vascular resistance
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rtPCR Reverse transcriptase polymerase chain reaction
RVSP right ventricular systolic pressure
RRT registered respiratory therapist
SBP systolic blood pressure
SNP single nucleotide polymorphism
VSM vascular smooth muscle
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Box 1
Inclusion and exclusion criteria for iNOPE
Inclusion
1. Age ≥18
2. Pulmonary imaging-proven PE, as interpreted by local radiologists.
3. At least one predictor of RV dysfunction
a. echocardiography with RV dilation or hypokinesis,
b. estimated RVSP > 40 mm Hg,
c. RV>LV on CTPA,
d. elevated troponin I (>0.1 ng/mL) or natriuretic peptide (BNP> 90 
pg/mL)
e. screening bedside cardiac ultrasound with color flow capability that 
shows RV dysfunction (must be included with another RV 
dysfunction predictor),
f. RV strain on ECG (Defined by a Daniel score >8)
4. Plan to admit to a bed with telemetry capability
Exclusion
1. Vasopressor support at time of enrollment
2. Pregnancy
3. Plan by clinical care team to use lytics or surgical embolectomy
4. Plan by clinical care team to use platelet inhibiting drugs
5. Contraindication to anticoagulation
6. Altered mental status such that the patient is unable to provide informed 
consent
7. Inability to use a nasal cannula
8. Comfort care measures instituted
9. Supplemental oxygen requirements greater than can be administered via nasal 
cannula in order to maintain SpO2>80%
10. Pneumothorax with decompression
11. Recent use of drugs known to increase cGMP
12. Use of nitroprusside or nitroglycerin within the last 4 hours
13. Use of any other long-acting nitrates within the past 24 hours
14. Use of a fibrinolytic medicine within the past 3 days
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15. At the discretion of the Principal Investigator
Kline et al. Page 15
Am Heart J. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Diagram of study hypothesis and integration of the clinical study and the basic science 
study. PE causes intracardiac hemolysis which disrupts NO signaling by scavenging NO and 
releasing arginase which depletes L-arginine, producing a negative feedback cycle of 
increased pulmonary VSM constriction, increased PVR, higher RV pressures and more 
hemolysis. Inhaled NO (iNO*) will break this cycle.
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Figure 2. 
Timeline and key measurements of the clinical study. Echo #1was optional. O2 delivery by 
nasal cannula can vary depending upon patient comfort.
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Figure 3. 
Protocol for administering and weaning study drug. Relative endpoints included persistent 
symptoms or signs, that in the judgment of the investigator, appeared to be worsened by 
increasing the inhaled NO ppm and improved by decreasing the inhaled NO ppm. Absolute 
endpoints included: respiratory distress prompting the clinical care team to plan for 
mechanical or noninvasive ventilatory support, hypoxemia (SaO2 < 90% for 15 min), 
circulatory shock (SBP< 90 mm Hg for 15 min in consecutive measurements), new 
neurologic signs or any ventricular arrhythmias or sustained supraventricular arrhythmia 
with hypotension or refractory to intravenous medication for more than one hour, ECG 
changes, MtHb >10% for more than one hour, or persistent vomiting).
The rapid wean protocol was an immediate halving of the inspired concentration and 
assessment of clinical status; if the patient were improved, the NO was reduced to 0 ppm.
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Figure 4. 
Power estimates assuming two effect sizes of 0.25 and 0.30 each with two different 
assumptions for p1 and p2
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